Doctor Peou Chenda

Directions

Doctor Peou Chenda Contact information, map and directions, contact form, opening hours, services, ratings, photos, videos and announcements from Doctor Peou Chenda, Medical and health, Svay Rieng, Svay Rieng.

αž€αŸ’αžšαž–αŸαž‰αž‘αžΈαžšαŸ‰αžΌαž’αž»αžΈαžβ€‹αž˜αž·αž“ β€œαžŸαŸ’αžšαŸ‚αž€αžŸαž»αŸ†αž‡αŸ†αž“αž½αž™β€ αž€αŸ’αž“αž»αž„αž˜αž½αž™αžαŸ’αž„αŸƒβ€‹αž‘αŸ αž”αŸ‰αž»αž“αŸ’αžαŸ‚αž˜αžΎαž›αž‘αŸ…αžαŸ’αžŸαŸ„αž™αžαž™αž”αž“αŸ’αžαž·αž…αž˜αŸ’αžαž„αŸ—β€‹αžŠαŸ„αž™αžŸαžΆαžšαž‘αž˜αŸ’αž›αžΆαž”αŸ‹αžŠαŸ‚αž›αž’αŸ’αžœαžΎαž‡αžΆαžšαŸ€αž„αžšαžΆαž›αŸ‹αžαŸ’αž„αŸƒαŸ” សូ...
27/12/2025

αž€αŸ’αžšαž–αŸαž‰αž‘αžΈαžšαŸ‰αžΌαž’αž»αžΈαžβ€‹αž˜αž·αž“ β€œαžŸαŸ’αžšαŸ‚αž€αžŸαž»αŸ†αž‡αŸ†αž“αž½αž™β€ αž€αŸ’αž“αž»αž„αž˜αž½αž™αžαŸ’αž„αŸƒβ€‹αž‘αŸ αž”αŸ‰αž»αž“αŸ’αžαŸ‚αž˜αžΎαž›αž‘αŸ…αžαŸ’αžŸαŸ„αž™αžαž™αž”αž“αŸ’αžαž·αž…αž˜αŸ’αžαž„αŸ—β€‹αžŠαŸ„αž™αžŸαžΆαžšαž‘αž˜αŸ’αž›αžΆαž”αŸ‹αžŠαŸ‚αž›αž’αŸ’αžœαžΎαž‡αžΆαžšαŸ€αž„αžšαžΆαž›αŸ‹αžαŸ’αž„αŸƒαŸ” αžŸαžΌαž˜αž…αžΆαž”αŸ‹αž•αŸ’αžαžΎαž˜αž”αŸ’αžŠαžΌαžšαž–αžΈαžšαžΏαž„αžαžΌαž…αŸ— αžŠαžΎαž˜αŸ’αž”αžΈαž€αžΆαžšαž–αžΆαžšαž€αŸ’αžšαž–αŸαž‰αž‘αžΈαžšαŸ‰αžΌαž’αž»αžΈαžαžšαž”αžŸαŸ‹αž’αŸ’αž“αž€β€¦

CT Scan Findings in Stroke & Hemorrhage1. Ischemic StrokeCT Findings: β€’ Area of hypodensity (dark area) β€’ Loss of gray–w...
10/11/2025

CT Scan Findings in Stroke & Hemorrhage

1. Ischemic Stroke

CT Findings:
β€’ Area of hypodensity (dark area)
β€’ Loss of gray–white differentiation
β€’ Sulcal effacement

Clinical Features:
β€’ Focal neurologic deficits
β€’ Headache may occur
β€’ ↓ Level of consciousness (LOC)

Examples:
β€’ L parietal ischemic stroke
β€’ Severe R-sided ischemic stroke

2. Intracerebral Hemorrhage (ICH)

CT Findings:
β€’ Hyperdense area (bright white blood)
β€’ Surrounding edema or mass effect

Clinical Features:
β€’ ↓ LOC
β€’ Major neurologic deficits
β€’ Severe headache
β€’ Nausea/Vomiting

Important:
βœ… Fibrinolytics are contraindicated

Example:
β€’ R parietal hemorrhage

3. Subarachnoid Hemorrhage (SAH)

CT Findings:
β€’ Blood in basal cisterns or cortical sulci

Clinical Features:
β€’ Sudden severe onset
β€’ β€œWorst headache of my life”
β€’ Neck stiffness
β€’ Nausea/Vomiting
β€’ ↓ LOC

Important:
βœ… Fibrinolytics are contraindicated

4. Subdural Hematoma (SDH)

CT Findings:
β€’ Crescent-shaped collection along the brain surface
β€’ Crosses suture lines

Clinical Features:
β€’ ↓ LOC
β€’ Drowsiness
β€’ Unequal or dilated pupils
β€’ Headache, N/V
β€’ Agitation, confusion, irritability

Important:
βœ… Fibrinolytics are contraindicated

Example:
β€’ L subdural blood

αžŸαžΆαžšαŸˆαžŸαŸ†αžαžΆαž“αŸ‹αž“αŸƒαž€αžΆαžšαž’αŸ’αžœαžΎαžαŸαžŸαŸ’αž HbA1c αž€αŸ’αž“αž»αž„αž€αžΆαžšαžαžΆαž˜αžŠαžΆαž“αž‡αŸ†αž„αžΊαž‘αžΉαž€αž“αŸ„αž˜αž•αŸ’αž’αŸ‚αž˜αžαžΎαž’αŸ’αž“αž€αž€αŸ†αž–αž»αž„αž”αžΆαžšαž˜αŸ’αž—αž’αŸ†αž–αžΈαž αžΆαž“αž·αž—αŸαž™αž“αŸƒαž‡αŸ†αž„αžΊαž‘αžΉαž€αž“αŸ„αž˜αž•αŸ’αž’αŸ‚αž˜ αž¬αž…αž„αŸ‹αž‚αŸ’αžšαž”αŸ‹αž‚αŸ’αžšαž„αž€...
01/11/2025

αžŸαžΆαžšαŸˆαžŸαŸ†αžαžΆαž“αŸ‹αž“αŸƒαž€αžΆαžšαž’αŸ’αžœαžΎαžαŸαžŸαŸ’αž HbA1c αž€αŸ’αž“αž»αž„αž€αžΆαžšαžαžΆαž˜αžŠαžΆαž“αž‡αŸ†αž„αžΊαž‘αžΉαž€αž“αŸ„αž˜αž•αŸ’αž’αŸ‚αž˜
αžαžΎαž’αŸ’αž“αž€αž€αŸ†αž–αž»αž„αž”αžΆαžšαž˜αŸ’αž—αž’αŸ†αž–αžΈαž αžΆαž“αž·αž—αŸαž™αž“αŸƒαž‡αŸ†αž„αžΊαž‘αžΉαž€αž“αŸ„αž˜αž•αŸ’αž’αŸ‚αž˜ αž¬αž…αž„αŸ‹αž‚αŸ’αžšαž”αŸ‹αž‚αŸ’αžšαž„αž€αž˜αŸ’αžšαž·αžαžŸαŸ’αž€αžšαž“αŸ…αž€αŸ’αž“αž»αž„αžˆαžΆαž˜αž²αŸ’αž™αž˜αžΆαž“αž”αŸ’αžšαžŸαž·αž‘αŸ’αž’αž—αžΆαž–αžŠαŸ‚αžšαž¬αž‘αŸ? αž€αžΆαžšαž’αŸ’αžœαžΎαžαŸαžŸαŸ’αž HbA1c αž‚αžΊαž‡αžΆαž§αž”αž€αžšαžŽαŸαžŠαŸαž˜αžΆαž“αž”αŸ’αžšαžŸαž·αž‘αŸ’αž’αž—αžΆαž–αž˜αž½αž™ αžŠαŸ‚αž›αž‡αž½αž™αž²αŸ’αž™αž’αŸ’αž“αž€αž™αž›αŸ‹αžŠαžΉαž„αž’αŸ†αž–αžΈαž€αž˜αŸ’αžšαž·αžαžŸαŸ’αž€αžšαž“αŸ…αž€αŸ’αž“αž»αž„αžˆαžΆαž˜αž€αŸ’αž“αž»αž„αžšαž™αŸˆαž–αŸαž›αžœαŸ‚αž„ αž αžΎαž™αž’αžΆαž…αž‡αž½αž™αž²αŸ’αž™αž’αŸ’αž“αž€αž’αŸ’αžœαžΎαž€αžΆαžšαžŸαž˜αŸ’αžšαŸαž…αž…αž·αžαŸ’αžαžαŸ’αžšαžΉαž˜αžαŸ’αžšαžΌαžœαžŸαž˜αŸ’αžšαžΆαž”αŸ‹αžŸαž»αžαž—αžΆαž–αžšαž”αžŸαŸ‹αž’αŸ’αž“αž€αŸ”

πŸ”Ή HbA1c (Hemoglobin A1c) αž‡αžΆαž€αžΆαžšαž’αŸ’αžœαžΎαžαŸαžŸαŸ’αžαžˆαžΆαž˜αžŠαžΎαž˜αŸ’αž”αžΈαžœαžΆαžŸαŸ‹αž”αžšαž·αž˜αžΆαžŽαžŸαŸ’αž€αžš (glucose) αžŠαŸ‚αž›αž—αŸ’αž‡αžΆαž”αŸ‹αž‡αžΆαž˜αž½αž™ hemoglobin αž€αŸ’αž“αž»αž„αž€αŸ„αžŸαž·αž€αžΆαžšαžˆαžΆαž˜αž€αŸ’αžšαž αž˜αŸ” αž–αžΈαž–αŸ’αžšαŸ„αŸ‡αž€αŸ„αžŸαž·αž€αžΆαžšαžˆαžΆαž˜αž€αŸ’αžšαž αž˜αž˜αžΆαž“αž’αžΆαž™αž»αž€αžΆαž›αž”αŸ’αžšαž αŸ‚αž› ៣ αžαŸ‚ αž€αžΆαžšαž’αŸ’αžœαžΎαžαŸαžŸαŸ’αž HbA1c αž“αžΉαž„αž”αž„αŸ’αž αžΆαž‰αž–αžΈαž€αž˜αŸ’αžšαž·αžαžŸαŸ’αž€αžšαž“αŸ…αž€αŸ’αž“αž»αž„αžˆαžΆαž˜αž‡αžΆαž˜αž’αŸ’αž™αž˜αžšαž”αžŸαŸ‹αž’αŸ’αž“αž€αž€αŸ’αž“αž»αž„αžšαž™αŸˆαž–αŸαž›αž”αŸ’αžšαž αŸ‚αž› ្-៣ αžαŸ‚αž…αž»αž„αž€αŸ’αžšαŸ„αž™αŸ”

πŸ‘‰ αž αŸαžαž»αž’αŸ’αžœαžΈαž”αžΆαž“αž‡αžΆ HbA1c αž˜αžΆαž“αžŸαžΆαžšαŸˆαžŸαŸ†αžαžΆαž“αŸ‹?
πŸ”Ή αžœαžΆαž™αžαž˜αŸ’αž›αŸƒαž€αž˜αŸ’αžšαž·αžαžŸαŸ’αž€αžšαžšαž™αŸˆαž–αŸαž›αžœαŸ‚αž„:
αž˜αž·αž“αžŠαžΌαž…αž“αžΉαž„αž€αžΆαžšαž’αŸ’αžœαžΎαžαŸαžŸαŸ’αžαžŸαŸ’αž€αžšαž“αŸ…αž€αŸ’αž“αž»αž„αžˆαžΆαž˜αž’αž˜αŸ’αž˜αžαžΆαž‘αŸ HbA1c αž’αžΆαž…αž”αž„αŸ’αž αžΆαž‰αžšαžΌαž”αž—αžΆαž–αž‘αžΌαž‘αŸ…αž“αŸƒαž€αž˜αŸ’αžšαž·αžαžŸαŸ’αž€αžšαž“αŸ…αž€αŸ’αž“αž»αž„αžˆαžΆαž˜αžšαž”αžŸαŸ‹αž’αŸ’αž“αž€αž€αŸ’αž“αž»αž„αžšαž™αŸˆαž–αŸαž› ្-៣ αžαŸ‚αž…αž»αž„αž€αŸ’αžšαŸ„αž™ αž‡αž½αž™αž²αŸ’αž™αž’αŸ’αž“αž€ αž“αž·αž„αžœαŸαž‡αŸ’αž‡αž”αžŽαŸ’αžŒαž·αžαžœαžΆαž™αžαž˜αŸ’αž›αŸƒαž”αŸ’αžšαžŸαž·αž‘αŸ’αž’αž—αžΆαž–αž“αŸƒαž€αžΆαžšαž‚αŸ’αžšαž”αŸ‹αž‚αŸ’αžšαž„αžŸαŸ’αž€αžšαž“αŸ…αž€αŸ’αž“αž»αž„αžˆαžΆαž˜αŸ”

πŸ”Ή αžšαž€αžƒαžΎαž‰αž‡αŸ†αž„αžΊαž‘αžΉαž€αž“αŸ„αž˜αž•αŸ’αž’αŸ‚αž˜αž¬αžŸαž—αžΆαž–αž˜αž»αž“αž‘αžΉαž€αž“αŸ„αž˜αž•αŸ’αž’αŸ‚αž˜αž”αžΆαž“αž˜αž»αž“:
αž€αžΆαžšαž’αŸ’αžœαžΎαžαŸαžŸαŸ’αž HbA1c αž’αžΆαž…αž‡αž½αž™αžšαž€αžƒαžΎαž‰αžŸαž—αžΆαž– αž˜αž»αž“αž‘αžΉαž€αž“αŸ„αž˜αž•αŸ’αž’αŸ‚αž˜ (αž“αŸ…αž–αŸαž›αž€αž˜αŸ’αžšαž·αž HbA1c αžαŸ’αž–αžŸαŸ‹αž‡αžΆαž„αž’αž˜αŸ’αž˜αžαžΆ αž”αŸ‰αž»αž“αŸ’αžαŸ‚αž˜αž·αž“αž‘αžΆαž“αŸ‹αžŠαž›αŸ‹αž€αž˜αŸ’αžšαž·αžαž‡αŸ†αž„αžΊαž‘αžΉαž€αž“αŸ„αž˜αž•αŸ’αž’αŸ‚αž˜) αž“αž·αž„αžšαž€αžƒαžΎαž‰αž‡αŸ†αž„αžΊαž‘αžΉαž€αž“αŸ„αž˜αž•αŸ’αž’αŸ‚αž˜αž“αŸ…αžŠαŸ†αžŽαžΆαž€αŸ‹αž€αžΆαž›αžŠαŸ†αž”αžΌαž„ αž‘αŸ„αŸ‡αž”αžΈαž‡αžΆαž˜αž·αž“αž˜αžΆαž“αžšαŸ„αž‚αžŸαž‰αŸ’αž‰αžΆαž…αŸ’αž”αžΆαžŸαŸ‹αž›αžΆαžŸαŸ‹αž€αŸαžŠαŸ„αž™αŸ”

πŸ”Ή αžαžΆαž˜αžŠαžΆαž“αž”αŸ’αžšαžŸαž·αž‘αŸ’αž’αž—αžΆαž–αž“αŸƒαž€αžΆαžšαž–αŸ’αž™αžΆαž”αžΆαž›αž‡αŸ†αž„αžΊαž‘αžΉαž€αž“αŸ„αž˜αž•αŸ’αž’αŸ‚αž˜:
αžŸαž˜αŸ’αžšαžΆαž”αŸ‹αž’αŸ’αž“αž€αžŠαŸ‚αž›αžαŸ’αžšαžΌαžœαž”αžΆαž“αžœαž·αž“αž·αž…αŸ’αž†αŸαž™αžαžΆαž˜αžΆαž“αž‡αŸ†αž„αžΊαž‘αžΉαž€αž“αŸ„αž˜αž•αŸ’αž’αŸ‚αž˜αžšαž½αž…αž αžΎαž™ αž€αžΆαžšαž’αŸ’αžœαžΎαžαŸαžŸαŸ’αž HbA1c αž‚αžΊαž‡αžΆαž§αž”αž€αžšαžŽαŸαžŸαŸ†αžαžΆαž“αŸ‹αž˜αž½αž™αž€αŸ’αž“αž»αž„αž€αžΆαžšαžαžΆαž˜αžŠαžΆαž“αž”αŸ’αžšαžŸαž·αž‘αŸ’αž’αž—αžΆαž–αž“αŸƒαž’αžΆαž αžΆαžš αž€αžΆαžšαž αžΆαžαŸ‹αž”αŸ’αžšαžΆαžŽ αž“αž·αž„αž€αžΆαžšαž”αŸ’αžšαžΎαžαŸ’αž“αžΆαŸ† αžŠαžΎαž˜αŸ’αž”αžΈαž€αŸ‚αžαž˜αŸ’αžšαžΌαžœαžœαž·αž’αžΈαž–αŸ’αž™αžΆαž”αžΆαž›αž²αŸ’αž™αžŸαž˜αžšαž˜αŸ’αž™αŸ”

πŸ”Ή αž–αŸ’αž™αžΆαž€αžšαžŽαŸαž αžΆαž“αž·αž—αŸαž™αž“αŸƒαž•αž›αžœαž·αž”αžΆαž€:
αž€αž˜αŸ’αžšαž·αž HbA1c αžαŸ’αž–αžŸαŸ‹αž”αž„αŸ’αž αžΆαž‰αžαžΆαž€αžΆαžšαž‚αŸ’αžšαž”αŸ‹αž‚αŸ’αžšαž„αžŸαŸ’αž€αžšαž“αŸ…αž€αŸ’αž“αž»αž„αžˆαžΆαž˜αž˜αž·αž“αž›αŸ’αž’ αžŠαŸ„αž™αž”αž“αŸ’αžαŸ‚αž˜αž αžΆαž“αž·αž—αŸαž™αž“αŸƒαž•αž›αžœαž·αž”αžΆαž€αžœαŸ‚αž„αžšαž™αŸˆαž–αŸαž› αžŠαžΌαž…αž‡αžΆ αž”αž‰αŸ’αž αžΆαž—αŸ’αž“αŸ‚αž€ αžαŸ†αžšαž„αž“αŸ„αž˜ αž”αŸ’αžšαžŸαžΆαž‘ αž“αž·αž„αž”αŸαŸ‡αžŠαžΌαž„αŸ”

πŸ‘‰ αž’αŸ’αž“αž€αžŽαžΆαžαŸ’αž›αŸ‡αž‚αž½αžšαž’αŸ’αžœαžΎαžαŸαžŸαŸ’αž HbA1c?
πŸ”Ή αž’αŸ’αž“αž€αžŠαŸ‚αž›αž˜αžΆαž“αž αžΆαž“αž·αž—αŸαž™αž“αŸƒαž‡αŸ†αž„αžΊαž‘αžΉαž€αž“αŸ„αž˜αž•αŸ’αž’αŸ‚αž˜ (αž˜αžΆαž“αž”αŸ’αžšαžœαžαŸ’αžαž·αž‚αŸ’αžšαž½αžŸαžΆαžšαž˜αžΆαž“αž‡αŸ†αž„αžΊαž“αŸαŸ‡ αžαŸ’αž›αžΆαž‰αŸ‹αžαŸ’αž–αžŸαŸ‹ αž¬αž˜αž·αž“αžŸαžΌαžœαž αžΆαžαŸ‹αž”αŸ’αžšαžΆαžŽ)αŸ”
πŸ”Ή αž’αŸ’αž“αž€αžŠαŸ‚αž›αž˜αžΆαž“αžšαŸ„αž‚αžŸαž‰αŸ’αž‰αžΆαžŸαž„αŸ’αžŸαŸαž™αžαžΆαž˜αžΆαž“αž‡αŸ†αž„αžΊαž‘αžΉαž€αž“αŸ„αž˜αž•αŸ’αž’αŸ‚αž˜ (αž“αŸ„αž˜αž‰αžΉαž€ αžƒαŸ’αž›αžΆαž“αž‘αžΉαž€αž‰αžΉαž€ αž¬αžŸαž˜αŸ’αžšαž€αž‘αŸ†αž„αž“αŸ‹αžŠαŸ„αž™αž˜αž·αž“αžŠαžΉαž„αž˜αžΌαž›αž αŸαžαž»)αŸ”
πŸ”Ή αž’αŸ’αž“αž€αžŠαŸ‚αž›αžαŸ’αžšαžΌαžœαž”αžΆαž“αžœαž·αž“αž·αž…αŸ’αž†αŸαž™αžαžΆαž˜αžΆαž“αž‡αŸ†αž„αžΊαž‘αžΉαž€αž“αŸ„αž˜αž•αŸ’αž’αŸ‚αž˜αžšαž½αž…αž αžΎαž™ αžŠαžΎαž˜αŸ’αž”αžΈαžαžΆαž˜αžŠαžΆαž“αž“αž·αž„αž‚αŸ’αžšαž”αŸ‹αž‚αŸ’αžšαž„αž‡αŸ†αž„αžΊαŸ”

πŸ‘‰ αž€αžΆαžšαž’αŸ’αžœαžΎαžαŸαžŸαŸ’αž HbA1c αž‚αžΊαž‡αžΆαžœαž·αž’αžΈαžŠαŸαž˜αžΆαž“αž”αŸ’αžšαžŸαž·αž‘αŸ’αž’αž—αžΆαž–αž˜αž½αž™αž€αŸ’αž“αž»αž„αž€αžΆαžšαž™αž›αŸ‹αžŠαžΉαž„αž’αŸ†αž–αžΈαžŸαŸ’αžαžΆαž“αž—αžΆαž–αžŸαŸ’αž€αžšαž“αŸ…αž€αŸ’αž“αž»αž„αžˆαžΆαž˜αžšαž”αžŸαŸ‹αž’αŸ’αž“αž€αŸ” αžŸαžΌαž˜αž–αž·αž—αžΆαž€αŸ’αžŸαžΆαž‡αžΆαž˜αž½αž™αžœαŸαž‡αŸ’αž‡αž”αžŽαŸ’αžŒαž·αžαžšαž”αžŸαŸ‹αž’αŸ’αž“αž€αž’αŸ†αž–αžΈαž€αžΆαžšαž’αŸ’αžœαžΎαžαŸαžŸαŸ’αžαž“αŸαŸ‡ αžŠαžΎαž˜αŸ’αž”αžΈαž‘αž‘αž½αž›αž”αžΆαž“αž€αžΆαžšαž–αŸ’αž™αžΆαž”αžΆαž› αž¬αž€αžΆαžšαž–αžΆαžšαž‡αŸ†αž„αžΊαž²αŸ’αž™αž‘αžΆαž“αŸ‹αž–αŸαž›αžœαŸαž›αžΆαŸ”

Zieve’s SyndromeDefinition:A triad of clinical findings seen in patients with alcoholic liver disease: 1. Hemolytic anem...
02/10/2025

Zieve’s Syndrome

Definition:
A triad of clinical findings seen in patients with alcoholic liver disease:
1. Hemolytic anemia
2. Jaundice (not solely due to hepatic failure, but also hemolysis)
3. Transient hyperlipidemia

Pathophysiology
β€’ Exact mechanism not fully clear.
β€’ Believed to result from:
β€’ Alcohol-induced liver injury β†’ impaired lipid metabolism.
β€’ Abnormal lipoproteins destabilize RBC membranes β†’ hemolysis.
β€’ Alcohol and acetaldehyde directly toxic to RBC membranes.

Clinical Features
β€’ Occurs in chronic alcoholics with acute alcoholic hepatitis or withdrawal.
β€’ Symptoms: jaundice, fatigue, abdominal pain, nausea, vomiting.
β€’ Lab findings:
β€’ Hemolytic anemia (↑ reticulocyte count, indirect bilirubin, LDH; ↓ haptoglobin).
β€’ Hyperlipidemia (transient, can normalize within days to weeks).
β€’ Abnormal liver function tests (AST > ALT, ↑ GGT).

Management
β€’ Alcohol cessation (mainstay).
β€’ Supportive care: fluids, nutrition, transfusion if severe anemia.
β€’ Lipid abnormalities usually resolve spontaneously once alcohol is stopped.
β€’ Important to differentiate from other causes of jaundice and anemia in alcoholics (e.g., GI bleeding, cirrhosis, hepatitis).

02/10/2025
02/10/2025
Cushing syndrome happens when the body has too much of the hormone cortisol for a long time. This can result from the bo...
02/10/2025

Cushing syndrome happens when the body has too much of the hormone cortisol for a long time. This can result from the body making too much cortisol, or from taking medicines called glucocorticoids, which affect the body the same way as cortisol.

Too much cortisol can cause some of the main symptoms of Cushing syndrome β€” a fatty hump between the shoulders, a rounded face, and pink or purple stretch marks on the skin. Cushing syndrome also can cause high blood pressure or bone loss. Sometimes, it can cause type 2 diabetes.

History and Examination of the Respiratory System
01/10/2025

History and Examination of the Respiratory System

Ascites = peritoneal fluid accumulation, most often from cirrhosis with portal hypertension. β€’ Pathophysiology: splanchn...
01/10/2025

Ascites = peritoneal fluid accumulation, most often from cirrhosis with portal hypertension.
β€’ Pathophysiology: splanchnic vasodilation β†’ RAAS activation β†’ sodium/water retention.
β€’ Diagnosis: exam + ultrasound + paracentesis with SAAG.
β€’ Initial management: sodium restriction + spironolactone/furosemide.
β€’ Refractory cases: paracentesis (with albumin) or TIPS.
β€’ Always exclude infection, malignancy, or TB in atypical cases.
β€’ Prognosis: ascites signals advanced liver disease and high risk of complications.

Hepatomegaly
30/09/2025

Hepatomegaly

A tumor marker test measures substances in blood, urine, or tumor tissue that may be produced by cancer cells or by the ...
30/09/2025

A tumor marker test measures substances in blood, urine, or tumor tissue that may be produced by cancer cells or by the body in response to cancer. It is most useful for monitoring a known cancer, estimating prognosis, and guiding therapy, rather than for general screening.
it is
Tumor markers are proteins, enzymes, hormones, or genetic changes associated with specific cancers and can be detected in body fluids or tumor tissue. Some markers are measured in blood or urine, while others are assessed on biopsy or surgical specimens as β€œtissue markers.”

it's used
β€’ Assessing disease burden and stage alongside imaging and pathology.
β€’ Monitoring response to treatment; falling levels often indicate effective therapy.
β€’ Detecting minimal residual disease or recurrence during follow-up.
β€’ Selecting targeted therapies when markers predict drug sensitivity.

Address

Svay Rieng
Svay Rieng

Website

Alerts

Be the first to know and let us send you an email when Doctor Peou Chenda posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share